Clinical Trial

Liposomal and Standard Bupivacaine in Thoracic Paravertebral Block for Post-Thoracoscopic Pain

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated January 9, 2026 (before its estimated January 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
I. Research purpose 1.1 Main Objective: To investigate the efficacy and safety of bupivacaine liposome thoracic paravertebral nerve block for postoperative analgesia after thoracoscopic lobectomy 1.2 Exploratory Objective: To investigate the noninferiority of bupivacaine liposomes in thoracic paravertebral nerve block with standard bupivacaine
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-07; most recent amendment 2026-01-07.
Status change: Not Yet Recruiting → Recruiting 2026-01-07
Trial Details
NCT Number NCT06165991
Lead Sponsor Yongtao Sun
Conditions Thoracic Paravertebral Block, Postoperative Analgesia, Thoracoscopic Lobectomy
Enrollment 496 participants
Start Date 2024-06-01
Primary Completion 2026-01-30 (estimated)
Study Completion 2026-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-09